Alkermes plc (ALKS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
ALKS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ALKS Revenue Analysis (2014–2025)
As of February 28, 2026, Alkermes plc (ALKS) generated trailing twelve-month (TTM) revenue of $1.48 billion, reflecting significant decline in growth of -10.6% year-over-year. The most recent quarter (Q4 2025) recorded $384.5 million in revenue, down 2.4% sequentially.
Looking at the longer-term picture, ALKS's 5-year compound annual growth rate (CAGR) stands at +7.3%, indicating steady revenue expansion. The company achieved its highest annual revenue of $1.66 billion in 2023.
Revenue diversification analysis shows ALKS's business is primarily driven by Vivitrol (40%), Aristada And Aristada Initio (31%), and Manufactured Product And Royalty (25%).
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY), ALKS has underperformed the peer group in terms of revenue growth. Compare ALKS vs UTHR →
Peer Comparison
Compare ALKS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALKSCurrent | $1.5B | -10.6% | +7.3% | 17.2% | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% | |
| ARQT | $376M | +91.3% | - | -3.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.48B | -5.2% | $1.27B | 86.3% | $254.0M | 17.2% |
| 2024 | $1.56B | -6.4% | $1.31B | 84.2% | $420.6M | 27.0% |
| 2023 | $1.66B | +49.6% | $1.41B | 84.8% | $414.1M | 24.9% |
| 2022 | $1.11B | -5.3% | $893.7M | 80.4% | $-6,089,000 | -0.5% |
| 2021 | $1.17B | +13.0% | $976.4M | 83.2% | $97.7M | 8.3% |
| 2020 | $1.04B | -11.3% | $860.4M | 82.8% | $-112,427,000 | -10.8% |
| 2019 | $1.17B | +7.0% | $990.6M | 84.6% | $-175,479,000 | -15.0% |
| 2018 | $1.09B | +21.1% | $917.9M | 83.9% | $-99,128,000 | -9.1% |
| 2017 | $903.4M | +21.1% | $748.6M | 82.9% | $-147,900,000 | -16.4% |
| 2016 | $745.7M | +18.7% | $613.6M | 82.3% | $-208,665,000 | -28.0% |
See ALKS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALKS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ALKS vs AGIO
See how ALKS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ALKS's revenue growth accelerating or slowing?
ALKS revenue declined -10.6% year-over-year, contrasting with the 5-year CAGR of +7.3%. TTM revenue fell to $1.5B. This reverses the prior growth trend.
What is ALKS's long-term revenue growth rate?
Alkermes plc's 5-year revenue CAGR of +7.3% reflects the variable expansion pattern. Current YoY growth of -10.6% is below this long-term average.
How is ALKS's revenue distributed by segment?
ALKS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.